General Information of Drug (ID: DM6ENSJ)

Drug Name
Tralokinumab
Synonyms CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Ulcerative colitis DD71 Phase 3 [2]
Asthma CA23 Phase 1/2 [3]
Drug Type
Monoclonal antibody
Sequence
>heavy chain
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNY
GQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTV
SSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQ
EGNVFSCSVMHEALHNHYTQKSLSLSLGK
>light chain
SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPER
FSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVLGQPKAAPSVTLF
PPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYL
SLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5-8 days [4]
Bioavailability
The bioavailability of drug is 76% [4]
Clearance
The clearance of drug is 0.149 L/day [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 22 days [4]
Metabolism
The drug is metabolized via the catabolism to smaller peptides and amino acids [4]
Vd
The volume of distribution (Vd) of drug is 4.2 L [4]
Cross-matching ID
DrugBank ID
DB12169
TTD ID
D0I1ZY
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Inhibitor [6]
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Modulator [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Atopic dermatitis
ICD Disease Classification EA80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 4.40E-01 2.46 1
Interleukin 13 receptor alpha-2 (IL13RA2) DTT IL13RA2 5.77E-05 4.14 2.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
3 ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers
4 Health Canada Product Monograph: Adtralza (tralokinumab) for subcutaneous injection
5 EMA Summary of Product Characteristics: Adtralza (tralokinumab) for subcutaneous injection
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.